The ‘Peptide for Life’ Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure across Europe

Biomarkers in Heart Failure with Preserved Ejection Fraction

“…A cardiac-centred approach to HFpEF diagnosis using NPs is a good starting point, and is actually promoted by the Heart Failure Association through the 'Peptide for Life' initiative. 165 However, a holistic approach including biomarkers that provide information on non-cardiac components of the HFpEF syndrome may enrich our understanding of the disease and may be useful in classifying HFpEF phenotypes/ endotypes that may guide patient selection in HFpEF trials (Figure 1). 166 Because of the risk of bias in current HFpEF biomarker studies, methodologically well-designed studies with a uniform reference diagnosis are urgently needed to determine the incremental value of circulating biomarkers for the diagnosis of HFpEF.…”

Pre‐discharge and early post‐discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC

“…Natriuretic peptides (NPs) have a major role in the diagnosis, risk stratification, and management of patients with AHF. 9,[38][39][40] They are important markers of congestion. 39,41,42 In addition to their values at the time of discharge, the change in NP concentration during hospitalization is a powerful predictor of post-discharge outcome 39,[41][42][43][44] (Figure 2).…”

“…23,85,92 The use of imaging may be particularly important at sites with limited availability of NP measurements for quick decision making and serial follow-up. 40,93 Integration of clinical assessment, laboratory exams and imaging is presented in Figure 2.…”

Unlocking the potential of natriuretic peptide testing in primary care: A roadmap for early heart failure diagnosis

“…14 By leveraging the local organization of primary care, national guidelines can be better implemented, leading to improved NP testing and early HF diagnosis. Finally, combined European and national initiatives, such as the Peptide for Life initiative, 16 can act as a foundation for designing local training programmes for healthcare professionals and public sector workers, and further move forward adoption of NP testing. Raising awareness among healthcare professionals is necessary but not sufficient for enhancing the adoption of NP testing in primary care; changing medical behaviour is equally crucial.…”